Health Care & Life Sciences » Biotechnology | ImmunoCellular Therapeutics Ltd.

ImmunoCellular Therapeutics Ltd. | Ownership

Companies that own ImmunoCellular Therapeutics Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Renaissance Technologies LLC
1,078,404
2.57%
56,300
0%
06/30/2018
The Vanguard Group, Inc.
285,154
0.68%
205,588
0%
06/30/2018
Citadel Advisors LLC
136,043
0.32%
-258,612
0%
06/30/2018
Virtu Financial BD LLC
124,195
0.3%
-107,541
0%
06/30/2018
Wedbush Securities, Inc. (Investment Management)
86,530
0.21%
0
0%
06/30/2018
First Allied Advisory Services, Inc.
40,000
0.1%
0
0%
06/30/2018
UBS Securities LLC
32,270
0.08%
-1,357
0%
06/30/2018
Invesco Capital Management LLC
12,365
0.03%
12,365
0%
06/30/2018
BlackRock Fund Advisors
672
0%
0
0%
06/30/2018
Tradewinds Capital Management LLC
200
0%
0
0%
06/30/2018

About ImmunoCellular Therapeutics

View Profile
Address
30721 Russell Ranch Road
Westlake Village California 91362
United States
Employees -
Website http://www.imuc.com
Updated 07/08/2019
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers. The company's lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. Its pipeline also includes ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T cells.